Evidence map›Paper›PMID 35433438›Full record

ArticleFrontiers in oncology2022

Icaritin Inhibits Migration and Invasion of Human Ovarian Cancer Cells

Lvfen Gao, Yuan Ouyang, Ruobin Li, Xian Zhang, Xuesong Gao, Shaoqiang Lin, Xiaoyu Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Frontiers in pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lvfen GaoDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Yuan OuyangDepartment of Obstetrics and Gynecology, Guangzhou Panyu Central Hospital, Guangzhou, China.
Ruobin LiDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Xian ZhangDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Xuesong GaoDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Shaoqiang LinIntegrated Traditional and Western Medicine Research Center, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Xiaoyu WangDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
First Affiliated Hospital of Jinan University · CNFirst Affiliated Hospital of Guangdong Pharmaceutical University · CNPanyu District Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OC) is the most lethal of all gynecologic malignancies with poor survival rates. Although surgical treatment and chemotherapy had advanced to improve survival, platinum-based chemoresistance remains a major hurdle in the clinical treatment of OC. The search for novel active ingredients for the treatment of drug-resistant OC is urgently needed. Here, we demonstrated that icaritin, the main active ingredient derived from the traditional Chinese herb

Indexed as

Aktdrug-resistanticaritininvasionmigrationmTORovarian cancer

Identifiers

PMID35433438
PMCPMC9010825
OpenAlexW4220799691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.